Outcome of Lung Transplantation Using Grafts From Donors Over 65 Years of Age.


Journal

The Annals of thoracic surgery
ISSN: 1552-6259
Titre abrégé: Ann Thorac Surg
Pays: Netherlands
ID NLM: 15030100R

Informations de publication

Date de publication:
10 2021
Historique:
received: 20 03 2020
revised: 02 09 2020
accepted: 07 10 2020
pubmed: 11 11 2020
medline: 15 10 2021
entrez: 10 11 2020
Statut: ppublish

Résumé

The outcome of lung transplantation (LT) is correlated with donor selection. A donor age of 65 years is classically considered a contraindication to lung procurement, and the results of LT from elderly donors remain to be established. This was a retrospective study of a prospectively maintained database including all LTs performed in a single institution (Bichat Hospital, University of Paris, Paris, France) from January 2014 to March 2019. Donors65 years of age or older were included in the elderly group, whereas donors younger than 65 years of age were included in the control group. The study group included 241 LTs, including 44 (18%) in the elderly group and 197 (82%) in the control group. As compared with the control group, the elderly group was characterized by the following: donors of shorter stature (166 cm vs 172 cm; P = .04) and with less smoking history (14% vs 40%; P = .001), less bronchoscopic abnormality (20% vs 36%; P = .042), and less chest opacity (16% vs 30%; P = .048); and recipients of shorter stature (166 cm vs 170 cm; P = .04) but with similar diagnoses and gravity. There was no significant difference between the groups in any of the outcomes studied, including primary graft dysfunction, 30-day mortality, 1-year survival, chronic lung allograft dysfunction-free survival, and overall survival. In univariate analysis, the Oto lung donor score was the only factor associated with 1-year survival (score of 6 in alive patients vs score of 7 in dead patients; P = .04); donor age 65 years old or older was not. Carefully selected lung grafts from donors 65 years of age or older are associated with outcomes similar to those reported with grafts from younger donors Grafts from older donors thus provide an interesting option to expand the donor pool during a shortage.

Sections du résumé

BACKGROUND
The outcome of lung transplantation (LT) is correlated with donor selection. A donor age of 65 years is classically considered a contraindication to lung procurement, and the results of LT from elderly donors remain to be established.
METHODS
This was a retrospective study of a prospectively maintained database including all LTs performed in a single institution (Bichat Hospital, University of Paris, Paris, France) from January 2014 to March 2019. Donors65 years of age or older were included in the elderly group, whereas donors younger than 65 years of age were included in the control group.
RESULTS
The study group included 241 LTs, including 44 (18%) in the elderly group and 197 (82%) in the control group. As compared with the control group, the elderly group was characterized by the following: donors of shorter stature (166 cm vs 172 cm; P = .04) and with less smoking history (14% vs 40%; P = .001), less bronchoscopic abnormality (20% vs 36%; P = .042), and less chest opacity (16% vs 30%; P = .048); and recipients of shorter stature (166 cm vs 170 cm; P = .04) but with similar diagnoses and gravity. There was no significant difference between the groups in any of the outcomes studied, including primary graft dysfunction, 30-day mortality, 1-year survival, chronic lung allograft dysfunction-free survival, and overall survival. In univariate analysis, the Oto lung donor score was the only factor associated with 1-year survival (score of 6 in alive patients vs score of 7 in dead patients; P = .04); donor age 65 years old or older was not.
CONCLUSIONS
Carefully selected lung grafts from donors 65 years of age or older are associated with outcomes similar to those reported with grafts from younger donors Grafts from older donors thus provide an interesting option to expand the donor pool during a shortage.

Identifiants

pubmed: 33171173
pii: S0003-4975(20)31881-6
doi: 10.1016/j.athoracsur.2020.10.018
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1142-1149

Investigateurs

Sandrine Boudinet (S)
Sylvain Jean-Baptiste (S)
Dan Longrois (D)
Brice Lortat-Jacob (B)
Philippe Montravers (P)
Alexy Tran Dinh (A)
Malika Hammouda (M)
Lucie Lefèvre (L)
Alice Savary (A)
Agnès Abadie (A)
Zohra Brouk (Z)

Informations de copyright

Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Auteurs

Régis Renard (R)

Department of Vascular Surgery, Thoracic Surgery, and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Antoine Girault (A)

Department of Vascular Surgery, Thoracic Surgery, and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Alla Avramenko-Bouvier (A)

Department of Vascular Surgery, Thoracic Surgery, and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Arnaud Roussel (A)

Department of Vascular Surgery, Thoracic Surgery, and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Pierre Cerceau (P)

Department of Vascular Surgery, Thoracic Surgery, and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Quentin Pellenc (Q)

Department of Vascular Surgery, Thoracic Surgery, and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Vincent Bunel (V)

Department of Pulmonology B and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Cendrine Godet (C)

Department of Pulmonology B and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Gilles Jebrak (G)

Department of Pulmonology B and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Jonathan Messika (J)

Department of Pulmonology B and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Philippe Montravers (P)

Department of Anesthesia and Surgical Intensive Care Medicine, Bichat Hospital, University of Paris, Paris, France.

Hervé Mal (H)

Department of Pulmonology B and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Yves Castier (Y)

Department of Vascular Surgery, Thoracic Surgery, and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France.

Pierre Mordant (P)

Department of Vascular Surgery, Thoracic Surgery, and Lung Transplantation, Bichat Hospital, University of Paris, Paris, France. Electronic address: pierre.mordant@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH